Safety and efficacy of carotid stenting in the very elderly
โ Scribed by Arthur Grant; Christopher White; Gary Ansel; Michael Bacharach; Christopher Metzger; Carlos Velez
- Publisher
- John Wiley and Sons
- Year
- 2009
- Tongue
- English
- Weight
- 159 KB
- Volume
- 75
- Category
- Article
- ISSN
- 1522-1946
No coin nor oath required. For personal study only.
โฆ Synopsis
Abstract
Background: Carotid artery stenting (CAS) has emerged as an alternative to carotid endarterectomy (CEA) in patients at high risk for complications from surgery. The very elderly (โฅ80โyearโold) are one subgroup of patients identified as being at increased risk for carotid surgery. However, there is concern that the very elderly are also at increased risk for complications of CAS. A stroke and death rate of 12% was reported in very elderly patients during the rollโin phase of Carotid Revascularization Endarterectomy versus Stent Trial (CREST). We are reporting on a large clinical series of CAS with independent neurological assessment in the very elderly. Methods: Between 1994 and 2008, a consecutive series of 418 CAS patients (โฅ80โyearโold) were treated at four highโvolume centers with extensive CAS experience. Independent neurologic assessment was performed after CAS procedures. Thirtyโday followโup information was available in 389 patients. Results: The average age was 83.2 ยฑ 2.8 years. Most patients were male (63.2%), and the target lesion carotid stenosis was asymptomatic in twoโthirds (68.2%) of patients. The majority of patients treated with CAS had a history of coronary artery disease (74.4%), hypertension (87.8%), and dyslipidemia (71.1%). One third (30.1%) were diabetic and more than half (56.5%) were current or former smokers. Embolic protection devices (EPD) were used in 78.7% of cases with the CAS procedure being performed before EPD availability being the most common reason for not using them. The overall 30โday incidence of stroke and death was 2.8% (11/389). The cumulative incidence of major cardiovascular events (stroke, death, or myocardial infarction) during that time period was 3.3% (13/389). Conclusions: This large series of CAS with independent neurologic assessment is convincing evidence that the very elderly (โฅ80 years) can safely undergo CAS with stroke and death rates comparable to younger patients. The key to obtaining these excellent results is that CAS be performed by high volume, experienced operators who exercise restraint regarding patient selection. ยฉ 2009 WileyโLiss, Inc.
๐ SIMILAR VOLUMES
The safety profile of fluvoxamine was assessed in 4843 elderly, mainly depressed patients (65 years or older; range 65 to 97 years) enrolled in worldwide post-marketing studies. This cohort of elderly patients was extracted from a population of 34 587 patients in whom the safety profile of fluvoxami